当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials.

Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials.

Abstract：

CONTEXT:The true level of influenza vaccine efficacy is controversial and many factors may influence its estimation. OBJECTIVES:To estimate the efficacy of vaccination of children and non-elderly adults for the prevention of influenza and to explore the impact of type of vaccine, age, degree of strain matching, influenza type and case ascertainment methods on vaccine efficacy estimates. DATA SOURCES:Medline and EmBase databases until October 2011. References of relevant articles were also reviewed. STUDY SELECTION:Controlled trials evaluating seasonal influenza vaccines and presenting incidence of laboratory-confirmed influenza illness were eligible. Studies exploring efficacy after experimental challenge, presenting duplicate data, employing group randomization, or focusing on special populations were excluded. DATA EXTRACTION:The vaccine effect on influenza prevention was evaluated by calculating Mantel-Haenszel risk ratios (RR) and using random-effects models. Vaccine efficacies were calculated for each comparison as (1-RR)×100. RESULTS:Thirty studies were included in one or more of a total of 101 analyses, comprising 88.468 study participants. There was evidence of heterogeneity in 49% of the analyses. Summary vaccine efficacy was 65% against any strain, 78% against matched strains and 55% against not-matched strains. Both live-attenuated and inactivated vaccines showed similar levels of protection against not-matched strains (60% and 55%, respectively). Live-attenuated vaccines performed better than inactivated vaccines in children (80% versus 48%), whereas inactivated vaccines performed better than live-attenuated vaccines in adults (59% versus 39%). There was a large difference (20%) in efficacy against influenza A (69%) and influenza B (49%) types for not-matched strains. Summary estimates of vaccine efficacy were highest when ascertainment was based on culture confirmation. CONCLUSION:Influenza vaccines are efficacious, but efficacy estimates depend on many variables including type of vaccine and age of vaccinees, degree of matching of the circulating strains to the vaccine, influenza type, and methods of case ascertainment.

journal_name

Vaccine

journal_title

Vaccine

authors

DiazGranados CA,Denis M,Plotkin S

doi

10.1016/j.vaccine.2012.10.084

subject

Has Abstract

pub_date

2012-12-17 00:00:00

pages

49-57

issue

1

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(12)01557-5

journal_volume

31

pub_type

杂志文章,meta分析,评审

相关文献

VACCINE文献大全
  • Addressing personal parental values in decisions about childhood vaccination: Measure development.

    abstract：OBJECTIVE:Evidence-based strategies to address vaccine hesitancy are lacking. Personal values are a measurable psychological construct that could be used to deliver personalized messages to influence vaccine hesitancy and behavior. Our objectives were to develop a valid, reliable self-report survey instrument to measur...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.08.009

    authors： Cataldi JR,Sevick C,Pyrzanowski J,Wagner N,Brewer SE,Narwaney KJ,Shoup JA,Resnicow K,Glanz J,Dempsey A,Kwan BM

    更新日期：2019-09-10 00:00:00

  • Antibodies against cell surface antigens as very potent immunological adjuvants.

    abstract：:We describe here two very potent adjuvant systems which are thought to work directly on antigen specific lymphocytes, thus by-passing the normal route for adjuvants, which is to activate antigen presenting cells (APCs) inducing release of inflammatory cytokines with resultant side effects of local and systemic reactog...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.01.105

    authors： Barr T,Carlring J,Hatzifoti C,Heath AW

    更新日期：2006-04-12 00:00:00

  • Indicators to assess National Immunization Technical Advisory Groups (NITAGs).

    abstract：:A National Immunization Technical Advisory Group (NITAG) is an expert advisory committee that provides evidence-based recommendations to the Ministry of Health (MoH) to guide immunization programs and policies. The World Health Organization (WHO), the Initiative for Supporting National Independent Immunization and Vac...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.01.047

    authors： Blau J,Sadr-Azodi N,Clementz M,Abeysinghe N,Cakmak N,Duclos P,Janusz C,Jauregui B,Mihigo R,Mosina L,Takashima Y,Senouci K

    更新日期：2013-05-28 00:00:00

  • Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector.

    abstract：:CD8(+) T-cell responses provide beneficial antiviral immunity against human immunodeficiency virus 1 (HIV-1). In this study, we show that intragastric vaccination with a Salmonella HIV-1 Env DNA vaccine vector generates Env-specific CD8(+) T-cells, both in mucosal and systemic lymphoid tissue. By contrast, intramuscul...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00330-9

    authors： Shata MT,Reitz MS Jr,DeVico AL,Lewis GK,Hone DM

    更新日期：2001-11-12 00:00:00

  • A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination.

    abstract：BACKGROUND:Vietnam has high endemic hepatitis B virus infection with >8% of adults estimated to have chronic infection. Hepatitis B vaccine was first introduced in the national childhood immunization program in 1997 in high-risk areas, expanded nationwide in 2002, and included birth dose vaccination in 2003. This surve...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.11.004

    authors： Nguyen TH,Vu MH,Nguyen VC,Nguyen LH,Toda K,Nguyen TN,Dao S,Wannemuehler KA,Hennessey KA

    更新日期：2014-01-03 00:00:00

  • Development and validation of a quantitative competitive ELISA for potency testing of equine anti rabies sera with other potential use.

    abstract：:In case of a bite by a rabies infected animal, the World Health Organisation recommends a prophylactic treatment including the administration of Human Rabies Immunoglobulins (HRIGs) or highly purified F(ab')2 fragments produced from Equine Rabies Immunoglobulin (F(ab')2 - ERIGs). According to international regulation,...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.04.086

    authors： Korimbocus J,Dehay N,Tordo N,Cano F,Morgeaux S

    更新日期：2016-06-14 00:00:00

  • Immunologic synergism with IL-2 and effects of cCHMIs on mRNA expression of IL-2 and IFN-gamma in chicken peripheral T lymphocyte.

    abstract：:Two compound Chinese herbal medicinal ingredients (cCHMIs) were prepared, respectively, with epimedium polysaccharide plus propolis flavone (cCHMIs 1) and astragalus polysaccharide plus ginsenoside (cCHMIs 2). In animal immune experiment, Newcastle disease vaccine was mixed, respectively, with two cCHMIs and IL-2 to v...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.07.005

    authors： Wang D,Li X,Xu L,Hu Y,Zhang B,Liu J

    更新日期：2006-11-30 00:00:00

  • Implementation of the Standards for adult immunization practice: A survey of U.S. Health care providers.

    abstract：:The revised Standards for Adult Immunization Practice ("Standards"), published in 2014, recommend routine vaccination assessment, strong provider recommendation, vaccine administration or referral, and documentation of vaccines administered into immunization information systems (IIS). We assessed clinician and pharmac...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.05.073

    authors： Granade CJ,Parker Fiebelkorn A,Black CL,Lutz CS,Srivastav A,Bridges CB,Ball SW,Devlin RG,Cloud AJ,Kim DK

    更新日期：2020-07-14 00:00:00

  • A comparative study of PENTA vaccine booster doses given at 12, 15, or 18 months of age.

    abstract：:For infants immunized with Haemophilus influenzae type b conjugate vaccines, booster immunization is usually recommended in the second year of life, typically between 12 and 18 months. This study assessed the effect of age at booster immunization on pre-immunization antibody trough levels and on subsequent responses, ...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0264-410x(98)00232-1

    authors： Scheifele DW,Guasparini R,Lavigne P

    更新日期：1999-02-12 00:00:00

  • Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.

    abstract：:The level of protection conferred by foot-and-mouth disease (FMD) vaccines in primovaccinated animals primarily depends on the potency of the vaccine and the relatedness of the vaccine strain and circulating field isolate. The "Gold Standard" FMD vaccine potency test is the in vivo test performed in the target species...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.04.034

    authors： Goris N,Maradei E,D'Aloia R,Fondevila N,Mattion N,Perez A,Smitsaart E,Nauwynck HJ,La Torre J,Palma E,De Clercq K

    更新日期：2008-06-25 00:00:00

  • Regulatory oversight of clinical trials in Africa: progress over the past 5 years.

    abstract：:Randomized controlled clinical trials represent the best way to establish the therapeutic or preventive value of medicines. This decade has seen a strong shift in the location of clinical trials from industrialized countries to developing countries, including many in Africa. However, without independent strong regulat...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.08.113

    authors： Maïga D,Akanmori BD,Chocarro L

    更新日期：2009-12-09 00:00:00

  • Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

    abstract：:ChimeriVax is a live, attenuated recombinant virus constructed from yellow fever (YF) 17D in which the envelope protein genes of YF 17D are replaced with the corresponding genes of another flavivirus. A ChimeriVax vaccine was developed against Japanese encephalitis (JE). A randomized, double-blind, outpatient study wa...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0264-410x(01)00457-1

    authors： Monath TP,McCarthy K,Bedford P,Johnson CT,Nichols R,Yoksan S,Marchesani R,Knauber M,Wells KH,Arroyo J,Guirakhoo F

    更新日期：2002-01-15 00:00:00

  • Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines.

    abstract：:The humoral response to synthetic peptide vaccines against Semliki Forest virus (SFV) in H-2d BALB/c mice was investigated with the enzyme linked immunosorbent assay and the pepscan technique. The peptide vaccines consisted of amino acid sequences 240-255 (B) and 137-151 (T) of the E2 membrane protein of SFV colinearl...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00038-3

    authors： Fernández IM,Harmsen M,Benaissa-Trouw BJ,Stuij I,Puyk W,Meloen RH,Snippe H,Kraaijeveld CA

    更新日期：1998-10-01 00:00:00

  • Mumps resurgences in the United States: A historical perspective on unexpected elements.

    abstract：:In 2006 the United States experienced the largest nationwide mumps epidemic in 20 years, primarily affecting college dormitory residents. Unexpected elements of the outbreak included very abrupt time course (75% of cases occurred within 90 days), geographic focality (85% of cases occurred in eight rural Midwestern sta...

    journal_title：Vaccine

    pub_type： 历史文章,杂志文章,评审

    doi：10.1016/j.vaccine.2009.06.109

    authors： Barskey AE,Glasser JW,LeBaron CW

    更新日期：2009-10-19 00:00:00

  • Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up.

    abstract：:In order to evaluate the long-term immunity 2 and 3 years after booster vaccination against tick-borne encephalitis (TBE) following time intervals 3 years and longer since last TBE immunization, 195 (mean age 50.5+/-15.1 years) and 240 subjects (mean age 47.0+/-15.4 years), respectively, who had received a single boos...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.01.116

    authors： Rendi-Wagner P,Paulke-Korinek M,Kundi M,Wiedermann U,Laaber B,Kollaritsch H

    更新日期：2007-06-28 00:00:00

  • Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

    abstract：:Optimal protection against malaria may require induction of high levels of protective antibody and CD8(+) and CD4(+) T cell responses. In humans, malaria DNA vaccines elicit CD8(+) cytotoxic T cells (CTL) and IFNgamma responses as measured by short-term (ex vivo) ELISPOT assays, and recombinant proteins elicit antibod...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.vaccine.2004.01.031

    authors： Epstein JE,Charoenvit Y,Kester KE,Wang R,Newcomer R,Fitzpatrick S,Richie TL,Tornieporth N,Heppner DG,Ockenhouse C,Majam V,Holland C,Abot E,Ganeshan H,Berzins M,Jones T,Freydberg CN,Ng J,Norman J,Carucci DJ,Cohen J

    更新日期：2004-04-16 00:00:00

  • Genetic diversity and population dynamics of Bordetella pertussis in China between 1950-2007.

    abstract：:Pertussis is an acute respiratory infectious disease caused by the bacterium Bordetella pertussis. Although pertussis vaccination was introduced in the 1960s, pertussis is still an endemic disease in China. To better understand the genetic diversity of the Chinese B. pertussis population, we characterized 115 clinical...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.09.040

    authors： Xu Y,Zhang L,Tan Y,Wang L,Zhang S,Wang J

    更新日期：2015-11-17 00:00:00

  • Global distribution of group A rotavirus strains in horses: a systematic review.

    abstract：:Group A rotavirus (RVA) is a major cause of diarrhea and diarrhea-related mortality in foals in parts of the world. In addition to careful horse farm management, vaccination is the only known alternative to reduce the RVA associated disease burden on horse farms. The precise evaluation of vaccine effectiveness against...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2013.08.045

    authors： Papp H,Matthijnssens J,Martella V,Ciarlet M,Bányai K

    更新日期：2013-11-19 00:00:00

  • The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa.

    abstract：OBJECTIVES:Persistent hepatitis B virus (HBV) infection is a major cause of morbidity and mortality in sub-Saharan Africa. The HIV epidemic has the potential to affect its biology. Immunisation protocols established in the pre-HIV era are based upon data showing predominantly horizontal infant transmission. This study ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.08.028

    authors： Andersson MI,Maponga TG,Ijaz S,Barnes J,Theron GB,Meredith SA,Preiser W,Tedder RS

    更新日期：2013-11-12 00:00:00

  • Pandemic influenza H1N1 2009 infection in Victoria, Australia: no evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009.

    abstract：:Conflicting findings regarding the level of protection offered by seasonal influenza vaccination against pandemic influenza H1N1 have been reported. We performed a test-negative case control study using sentinel patients from general practices in Victoria to estimate seasonal influenza vaccine effectiveness against la...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.03.055

    authors： Kelly HA,Grant KA,Fielding JE,Carville KS,Looker CO,Tran T,Jacoby P

    更新日期：2011-08-26 00:00:00

  • Hepatitis B vaccination: universal vaccination of newborn babies and children at 12 years of age versus high risk groups. A comparison in the field.

    abstract：:From 1983 to 1993 two anti-hepatitis B vaccinal strategies were adopted in two small towns of Southern Italy at high incidence for HBV infections: Afragola (prevalence of HBsAg carriers of 13.4%) and Frattamaggiore (prevalence of HBsAg carriers of 12.9%). In Afragola, the universal vaccination of infants in their firs...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(95)00056-7

    authors： Da Villa G,Picciottoc L,Elia S,Peluso F,Montanaro F,Maisto T

    更新日期：1995-09-01 00:00:00

  • Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits.

    abstract：:The next-generation human anthrax vaccine developed by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) is based upon purified Bacillus anthracis recombinant protective antigen (rPA) adsorbed to aluminum hydroxide adjuvant (Alhydrogel). In addition to being safe, and effective, it is...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.02.013

    authors： Ribot WJ,Powell BS,Ivins BE,Little SF,Johnson WM,Hoover TA,Norris SL,Adamovicz JJ,Friedlander AM,Andrews GP

    更新日期：2006-04-24 00:00:00

  • Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.

    abstract：:We assessed HPV 16 and 18 antibody responses of female subjects enrolled in a 2- vs. 3-dose quadrivalent HPV (Q-HPV) vaccine trial (ClinicalTrials.gov NCT00501137) using the Merck competitive Luminex (cLIA) and total IgG Luminex (TIgG) immunoassays, and a pseudovirus neutralizing antibody (PsV NAb) assay. Subjects wer...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2013.09.007

    authors： Krajden M,Cook D,Yu A,Chow R,Su Q,Mei W,McNeil S,Money D,Dionne M,Palefsky J,Karunakaran K,Kollmann T,Ogilvie G,Petric M,Dobson S

    更新日期：2014-01-23 00:00:00

  • A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.

    abstract：:In a phase I clinical trial, one hundred healthy young adults were randomized to receive two doses 28 days apart of an inactivated, subvirion vaccine containing 15 or 45microg of influenza A/H5N1 hemagglutinin (HA) by the intramuscular (IM) route, or 3 or 9microg of H5 HA by the intradermal(ID) route. Seventy-seven su...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2009.10.152

    authors： Patel SM,Atmar RL,El Sahly HM,Cate TR,Keitel WA

    更新日期：2010-04-09 00:00:00

  • Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV.

    abstract：:Successes for neutralizing antibodies (nAbs) against the human immunodeficiency virus (HIV) include potent cross-clade neutralization of primary virus isolates by human neutralizing monoclonal antibodies (nmAbs) targeting conserved envelope epitopes. Furthermore, passively administered combinations of human nmAbs prev...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/s0264-410x(02)00389-4

    authors： Ferrantelli F,Rasmussen RA,Hofmann-Lehmann R,Xu W,McClure HM,Ruprecht RM

    更新日期：2002-12-19 00:00:00

  • Long-term seropositivity, safety, and impact of inactivated and live, attenuated hepatitis a vaccines in China - A cross-sectional study.

    abstract：BACKGROUND:In 2008, China introduced live, attenuated hepatitis A vaccine (L-HepA, licensed in 1992) and inactivated hepatitis A vaccine (I-HepA, licensed in 2002) nationwide, and is currently the only country using L-HepA in routine immunization. We assessed seropositivity and its duration following vaccination, safet...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.11.019

    authors： Xiaojin S,Rodewald LE,Guomin Z,Hui Z,Ning M,Fuzhen W,Zundong Y

    更新日期：2020-12-14 00:00:00

  • Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate.

    abstract：:Vaccination is considered the most cost-effective approach to preventing infectious diseases, yet better formulations and delivery methods for efficient distribution and administration of vaccines are needed, especially for low-resource settings. A fast-dissolving tablet (FDT) that could be packaged in a compact stack...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.08.010

    authors： Lal M,Priddy S,Bourgeois L,Walker R,Pebley W,Brown J,Desai J,Darsley MJ,Kristensen D,Chen D

    更新日期：2013-10-01 00:00:00

  • New vaccine introductions in Africa before and during the decade of vaccines - Are we making progress?

    abstract：:Vaccines are excellent investments with far-reaching rewards beyond individual and population health, but their introduction into national programs has been historically slow in Africa. We provide an overview of the introduction of new and underutilized vaccines in countries of the WHO African Region by 2017, using da...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.05.002

    authors： Sambala EZ,Wiyeh AB,Ngcobo N,Machingaidze S,Wiysonge CS

    更新日期：2019-05-31 00:00:00

  • Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.

    abstract：:Since preexisting immunity and enhanced infection rates in a clinical trial of an HIV vaccine have raised some concerns on adenovirus (Ad) serotype 5-based vaccines, we evaluated the subgroup D adenovirus serotype Ad19a for its suitability as novel viral vector vaccine against mucosal infections. In BALB/c mice, we co...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.02.075

    authors： Lapuente D,Ruzsics Z,Thirion C,Tenbusch M

    更新日期：2018-05-03 00:00:00

  • Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.

    abstract：:It has been hypothesized that antibody induced by Plasmodium falciparum circumsporozoite protein vaccine would be effective against endemic human malaria. In a malaria endemic region of Kenya, 76 volunteers, in 38 pairs sleeping adjacently, were immunized with subunit circumsporozoite protein Asn-Ala-Asn-Pro tetrapept...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/0264-410x(95)00221-l

    authors： Sherwood JA,Copeland RS,Taylor KA,Abok K,Oloo AJ,Were JB,Strickland GT,Gordon DM,Ballou WR,Bales JD Jr,Wirtz RA,Wittes J,Gross M,Que JU,Cryz SJ,Oster CN,Roberts CR,Sadoff JC

    更新日期：1996-06-01 00:00:00